L-M Tseng

428 citations
20 papers · 223 · h-index 6

Impact in

Papers in

  • Oncology 15
    • HER2/EGFR in Cancer Research 9
    • Cancer Treatment and Pharmacology 7
  • Pulmonary and Respiratory Medicine 11
    • Advanced Breast Cancer Therapies 6
    • Lung Cancer Treatments and Mutations 3
    • Brain Metastases and Treatment 3
Co-authors
MC Liu (2 shared papers)Tadeusz Pieńkowski (2 shared papers)L Roman (2 shared papers)Tania Szado (2 shared papers)Y-H Im (2 shared papers)Luca Gianni (2 shared papers)Javier Cortés (3 shared papers)Y.H. Park (4 shared papers)
Journals
Cancer Research (10 papers)Annals of Oncology (8 papers)Value in Health (1 paper)PubMed (1 paper)
Partner nations
TaiwanSouth KoreaUnited States

In The Last Decade

L-M Tseng

18 papers receiving 220 citations

Peers

L-M Tseng
Comparison fields: 5 of 33
  • Oncology 194
  • Radiology, Nuclear Medicine and Imaging 76
  • Cancer Research 48
  • Genetics 28
  • Pulmonary and Respiratory Medicine 85
Replace Hiroji Iwata with:
Hiroji Iwata Japan
C. Saura Manich Spain
Brooke Daniel United States
Shakeela Bahadur United States
Christoph Meyenberg Switzerland
Hannah Dzimitrowicz United States
Míriam Arumí Spain
Sonja Heibl Austria
Rinat Yerushalmi Israel
Julie Taguchi United States
L-M Tseng relative to Hiroji Iwata Japan Hiroji Iwata's profile →
Citations per field
00.5×2×3×4×
Hiroji Iwata · 1×
Citations per year

Countries citing papers authored by L-M Tseng

Since Specialization
Citations

This map shows the geographic impact of L-M Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L-M Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L-M Tseng more than expected).

Fields of papers citing papers by L-M Tseng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L-M Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L-M Tseng. The network helps show where L-M Tseng may publish in the future.

Co-authors

The 25 scholars most cited alongside L-M Tseng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with L-M Tseng Line = papers co-authored together L-M Tseng links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study
Annals of Oncology ·Javier Cortés, S-B. Kim, W-P. Chung, S-A. Im, Y.H. Park, Roberto Hegg, Minjung Kim, L-M Tseng, Vanessa Petry, C-F. Chung, Hiroji Iwata, E.P. Hamilton, Giuseppe Curigliano, Binghe Xu, C. Lee, Y. Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz
202173
2
Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')
Cancer Research ·Luca Gianni, Tadeusz Pieńkowski, Y-H Im, L Roman, L-M Tseng, MC Liu, A. Lluch-Hernández, Semiglazov Vf, Tania Szado, G. Ross
201048
3
S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).
Cancer Research ·Luca Gianni, Giampaolo Bianchini, Astrid Kiermaier, Giulia Bianchi, Y-H Im, Tadeusz Pieńkowski, L Roman, MC Liu, L-M Tseng, Jithendra Ratnayake, Tania Szado, G. Ross, Pinuccia Valagussa
201133
4
377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
Annals of Oncology ·S.A. Hurvitz, Shanu Modi, Wěi Li, Y.H. Park, Wei‐Pang Chung, S-B. Kim, Javier Cortés, Toshinari Yamashita, José Luiz Pedrini, S-A. Im, L-M Tseng, Nadia Harbeck, I. Krop, G. Curigliano, E. Mathias, Jillian Cathcart, A. Cagnazzo, Shahid Ashfaque, Anton Egorov, Fabrice André
202324
5
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
Annals of Oncology ·Fabrice André, Javier Cortés, G. Curigliano, S. Modi, Wěi Li, Y.H. Park, W-P Chung, S.-B. Kim, Toshinari Yamashita, José Luiz Pedrini, S-A Im, L-M Tseng, N. Harbeck, Ian E. Krop, S. Nakatani, Kristen M. Tecson, Shahid Ashfaque, Anton Egorov, S.A. Hurvitz
202415
6
Kynurenine-3-monooxygenase (KMO) protein promotes triple negative breast cancer progression
Annals of Oncology ·Chia‐Yang Liu, T-T Huang, Chi‐Hang Lee, Wang Wl, HC Lee, L-M Tseng
20175
7
Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy
Annals of Oncology ·S.C. Lee, S-C. Chen, M-S Dai, G.E. Lee, CL Liu, Arlene Chan, H-K Chang, L-M Tseng, Wen Yee Chay, Louis WC Chow, J.L. Peneyra, K-M Rau, Hao‐Chien Wang, Adonis A. Guancia, M Head, Joanne Chiu, Bridget A. Robinson, Bertil Lindmark, Nicola McIntyre, C.I Hsieh
20175
8
Abstract P4-13-27: A phase Ib dose de-escalation study of combined tamoxifen and goserelin acetate with alpelisib (BYL719) or buparlisib (BKM120) in premenopausal patients with HR+/HER2– locally advanced or metastatic breast cancer
Cancer Research ·Yen‐Shen Lu, Jungsil Ro, L-M Tseng, T-Y. Chao, Imjai Chitapanarux, Roberta Valenti, Aycin Canatar, H. Salomon, YH Park
20164
9
The surgical treatment and prognostic factors of well-differentiated thyroid cancers in Chinese patients: a 20-year experience.
PubMed ·L-M Tseng, Lee Ch, Hao‐Chien Wang, Shyr Ym, Chiu Jh, Wu Cw, Lui Wy, P'eng Fk
19963
10
Abstract OT1-1-17: LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab and/or lapatinib*
Cancer Research ·Tamas Hickish, A Mehta, Minish Jain, Chiun‐Sheng Huang, Н. В. Коваленко, Dmitry Udovitsa, Karine Pemberton, Martina Uttenreuther‐Fischer, L-M Tseng, (unknown)
20123
11
Abstract P3-05-19: Regorafenib induces immunogenic cell death via p-stat3 inhibition in triple negative breast cancer cells
Cancer Research ·Chia‐Yang Liu, K-Y Lau, T-T Huang, Ji‐Long Chen, Pei‐Yi Chu, C.‐C. Huang, Wang Wl, L-M Tseng
20182
12
PCN16 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR HER-2 POSITIVE EARLY BREAST CANCER IN TAIWAN
Value in Health ·T-Y. Chao, Shuo Chen, K. D. Chang, Hsiang‐Kuang Chang, D.R. Chen, MF Hou, Hsieh Rk, WT Huang, L-M Tseng, Hao‐Chien Wang, Lu Yang, A Cirrincione
20072
13
555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study
Annals of Oncology ·Peter Schmid, Hao‐Chien Wang, F. Lynce, Y.H. Park, X. Cynthia, K.H. Jung, S.C. Chen, MF Hou, Catherine Prady, L-M Tseng, Jamil Asselah, Piotr J. Wysocki, Simon Lord, P. Rao-Melacini, Ross Stewart, Karola Warzyszyńska, Petra Vuković, S-A. Im
20251
14
Abstract PD07-02: βIII Tubulin Expression by Immunohistochemistry (IHC) and mRNA in a Randomized Phase 2 Neoadjuvant Breast Cancer (BC) Study of Ixabepilone (ixa) Compared to Paclitaxel (pac)
Cancer Research ·Christine E. Horak, Lajos Pusztai, Boyd Mudenda, Guo Xing, Ovidiu C. Trifan, Cristina Saura, L-M Tseng, Siu‐Ki Chan, Rosanne Welcher, D. Liu
20101
15
Abstract PD07-01: Phase 2 Study of Ixabepilone Versus Paclitaxel as Neoadjuvant Therapy for Early Stage Breast Cancer with Comparative Biomarker Analysis
Cancer Research ·Cristina Saura, L-M Tseng, Sherry Kit Wa Chan, RT Chacko, Mario Campone, D Liu, J Mukhopadhyay, Boyd Mudenda, Christine E. Horak, Guo Xing, Lajos Pusztai
20101
16
Abstract P5-21-13: Olaparib monotherapy versus chemotherapy for patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: Asian subgroup analysis from the phase III OlympiAD trial
Cancer Research ·S-A. Im, Binghe Xu, W. Li, Mark E. Robson, Quchang Ouyang, D-C Yeh, Hiroji Iwata, YH Park, JH Sohn, L-M Tseng, Carsten Goessl, Wencheng Wu, Sarah Runswick, Norikazu Masuda
20181
17
Abstract P2-08-25: Impact of kynurenine 3-monooxygenase expression on outcome in patients with triple-negative breast cancer undergone primary treatments
Cancer Research ·C.F. Wu, Pei‐Yi Chu, Wang Wl, Chia‐Yang Liu, L-M Tseng
20161
18
Abstract P2-16-02: Bevacizumab, etoposide, and cisplatin (BEEP) is highly effective in brain metastases of HER2 positive breast cancer progressing from whole brain radiotherapy - Subgroup analysis of a multi-center phase II study
Cancer Research ·Yen‐Shen Lu, W-W Chen, Ching‐Hsiung Lin, D-C Yeh, L-M Tseng, K-M Rau, Bang‐Bin Chen, T-C Chao, Wu Pf, S-M. Huang, TT-F Shih, Chiun‐Sheng Huang, Ann‐Lii Cheng
20131
19
LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort
Annals of Oncology ·Xingjiang Hu, Qingfu Zhang, Tao Sun, Hua Xiong, Wei Li, Yanling Teng, Yen‐Shen Lu, L-M Tseng, M. Yan, Han Li, Da Pang, S.C. Chen, Wei Chen, Ou Jiang, Jianliu Wang, Xianghua Wu, E. Fan, Jiang Lin, Xin Zeng, Nicholas C. Turner
20230
20
16P Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Annals of Oncology ·J-I. Lai, Yoland Antill, K.H. Jung, Carlos Shimizu, Ma. Lourdes A. Tiambeng, L-M Tseng, E.M. Tan, Shunlin Qu, Carmel Spiteri, Soo Yeon Ihm, David S. Hsu
20230

About L-M Tseng

L-M Tseng is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics and Molecular Biology, having authored 20 papers that have together received 223 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (5 papers), Lung Cancer Treatments and Mutations (3 papers), Brain Metastases and Treatment (3 papers), Tryptophan and brain disorders (2 papers) and BRCA gene mutations in cancer (2 papers). The work is most often cited by research in Oncology (194 citations), Radiology, Nuclear Medicine and Imaging (76 citations), Cancer Research (48 citations), Genetics (28 citations) and Pulmonary and Respiratory Medicine (85 citations). L-M Tseng has collaborated with scholars based in Taiwan, South Korea and United States. Frequent co-authors include MC Liu, Tadeusz Pieńkowski, L Roman, Tania Szado, Y-H Im, Luca Gianni, Javier Cortés, Y.H. Park, G. Ross and Semiglazov Vf. Their work appears in journals such as Cancer Research, Annals of Oncology, Value in Health and PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroji IwataBreakdown of academic impact, for papers by C. Saura ManichBreakdown of academic impact, for papers by Brooke DanielBreakdown of academic impact, for papers by Shakeela BahadurBreakdown of academic impact, for papers by Christoph MeyenbergBreakdown of academic impact, for papers by Hannah DzimitrowiczBreakdown of academic impact, for papers by Míriam ArumíBreakdown of academic impact, for papers by Sonja HeiblBreakdown of academic impact, for papers by Rinat YerushalmiBreakdown of academic impact, for papers by Julie Taguchi